JPRN-UMIN000015733CompletedPhase 1
Safety of cell immunotherapy for refractory malignant tumor using natural killer cell-like effector cells (CA-MED-NK001) selectively amplified from autologous mononuclear cells in peripheral blood - Safety of cell immunotherapy for refractory malignant tumor using CA-MED-NK001 cells
Center for Advanced Medical Innovation, Kyushu University0 sites10 target enrollmentStarted: November 21, 2014Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 10
Study Overview
Brief Summary
This trial has been terminated due to the difficulties of the recruitment of condition-matched subjects after the entry of four patients.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients to be excluded would satisfy any of the following conditions: (1) pulmonary fibrosis and/or interstitial pneumonia (2) patients who have a history of severe drug allergy (3) serum positive for HBs antigen, HCV, HTLV-1 and/or HIV antibody (4) active autoimmune disease (5) patients who are taking steroids and/or immunosuprresive agents (6) double or more cancers (7) uncontrolable infectious disease (8) Patients to be or wishing for pregnancy, or breast-feeding (9) T cell- or NK cell-originated leukemia and/or lymphoma (10) heavy cardiological disease (11) Patientss who are regarded as inadequate for study enrollment by the investigator
Investigators
Similar Trials
Completed
Phase 1
Combination therapy with immune-cell therapy and immune check point inhibitor.malignant tumorJPRN-jRCTc031210185Takimoto Rishu3
Completed
Phase 2
Combination therapy with immune-cell therapy and immune check point inhibitormalignant tumorJPRN-jRCTc031190100Takimoto Rishu40
Completed
Phase 2
Combination therapy with immune-cell therapy and immune check point inhibitormalignant tumorJPRN-jRCTc031190098Takimoto Rishu40
Completed
Phase 2
Combination therapy with immune-cell therapy and immune check point inhibitormalignant tumorJPRN-jRCTc031190099Takimoto Rishu40
Completed
Phase 2
A phase II study of palliative chemoradiation therapy with paclitaxel and cisplatin for local symptoms due to an unresectable primary advanced or locally recurrent gastric adenocarcinomagastric cancerJPRN-UMIN000003201Study group of multi-modality therapy for gastric cancer5
